scn4ab Antibody

Basic Research Questions

• What is SCN4B and why is it important in research?

  SCN4B (Sodium Channel, Voltage-Gated, Type IV, beta Subunit) functions as a regulatory subunit of multiple voltage-gated sodium (Nav) channels that directly mediate the depolarization of excitable membranes. It plays a critical role in modulating channel gating kinetics by causing negative shifts in the voltage dependence of activation of certain alpha sodium channels without affecting the voltage dependence of inactivation . The importance of SCN4B in research stems from its involvement in various physiological processes, including action potential generation, cell excitability, and epithelial organization, making it relevant for studies in neuroscience, muscle physiology, and cancer research .

• What species reactivity is available for SCN4B antibodies?

  Current commercial SCN4B antibodies show reactivity with various species:

  Antibody Catalog ID	Species Reactivity	Applications
  ABIN6242071	Human, Mouse, Rat	WB
  A100775	Human	WB, ELISA
  ASC-044	Rat, Mouse, Human	WB, IHC, Flow cytometry
  ab219816	Human	WB, IHC-P

  When selecting an antibody, verify the target species' sequence homology with the immunogen used to generate the antibody . Most commercially available antibodies are raised against human, mouse, or rat SCN4B epitopes, with varying degrees of cross-reactivity.

• What are the common applications for SCN4B antibodies?

  SCN4B antibodies are utilized in various experimental techniques:

  • Western Blotting (WB): Commonly used at dilutions ranging from 1:500-1:3000, depending on the specific antibody

  • Enzyme-Linked Immunosorbent Assay (ELISA): Typically at higher dilutions (e.g., 1:10000)

  • Immunohistochemistry (IHC): For tissue section analysis, including formalin-fixed paraffin-embedded samples

  • Immunofluorescence (IF): For cellular localization studies

  • Immunocytochemistry (ICC): For cultured cell studies

  • Flow Cytometry: For cell surface detection in intact cells

  Most SCN4B antibodies detect a protein of approximately 24 kDa molecular weight .

Advanced Research Questions

• How can I validate the specificity of SCN4B antibodies in my experimental system?

  Validating antibody specificity is critical for ensuring reliable results. A comprehensive validation approach includes:

  1. Peptide competition assays: Pre-incubate the antibody with the immunizing peptide before application. This should abolish specific staining, as demonstrated with Anti-SCN4B (Navβ4) antibody when pre-incubated with SCN4B/Navβ4 blocking peptide .

  2. Positive and negative controls: Use tissues or cell lines known to express (e.g., HepG2, Jurkat cells) or not express SCN4B. For example, Western blot analysis has shown SCN4B expression in HepG2 cells that can be blocked with the immunizing peptide .

  3. Knockdown/knockout validation: Compare staining in wildtype samples versus those with reduced SCN4B expression (via siRNA, shRNA, or CRISPR-Cas9).

  4. Multiple antibody approach: Use antibodies targeting different epitopes of SCN4B to confirm results.

  5. Cross-species validation: When possible, confirm consistent patterns across homologous proteins in different species, as seen with Anti-SCN4B antibodies that detect the protein in rat, mouse, and human samples .

• What are the technical considerations for using SCN4B antibodies in Western blotting?

  Optimizing Western blot protocols for SCN4B detection requires attention to several technical factors:

  1. Sample preparation:

     • For membrane proteins like SCN4B, use appropriate lysis buffers containing mild detergents that preserve membrane protein integrity

     • Include protease inhibitors to prevent degradation

  2. Dilution optimization:

     • Start with the manufacturer's recommended dilution range (typically 1:500-1:3000)

     • Perform a titration experiment to determine optimal signal-to-noise ratio

  3. Blocking conditions:

     • 5% non-fat dry milk or BSA in TBST is typically effective

     • Some antibodies may require specific blocking reagents

  4. Detection considerations:

     • SCN4B migrates at approximately 24 kDa

     • Longer exposure times may be needed for tissues with lower expression

     • Secondary antibody selection should match the host species (typically rabbit for most commercial SCN4B antibodies)

• How do SCN4B and SCN4A antibodies differ, and when should each be used?

  SCN4B and SCN4A target different subunits of voltage-gated sodium channels with distinct functions and expression patterns:

  Characteristic	SCN4B Antibodies	SCN4A Antibodies
  Target	Beta-4 regulatory subunit	Alpha pore-forming subunit
  Molecular Weight	~24 kDa	>200 kDa
  Primary Function	Modulates channel gating kinetics	Forms the ion-conducting pore
  Expression Pattern	Various tissues including epithelial cells	Primarily skeletal muscle
  Research Applications	Cancer studies, epithelial biology	Myotonia, periodic paralysis disorders

  Choose SCN4B antibodies when investigating regulatory aspects of sodium channel function, epithelial phenotype maintenance, or cancer progression . Use SCN4A antibodies when studying skeletal muscle excitability, neuromuscular junction formation, or related disorders like myotonia and periodic paralysis .

• What is the role of SCN4B in epithelial tissues, and how can antibodies help investigate this function?

  Recent research has revealed that SCN4B plays an important role in maintaining epithelial phenotype that extends beyond its traditional function in regulating sodium channels:

  1. Epithelial organization: SCN4B expression is necessary for proper epithelial morphology and the formation of organized three-dimensional structures. Reducing Na_Vβ4 expression in MCF10A non-cancer mammary epithelial cells disrupts epithelial organization in 3D cysts .

  2. Cell-cell adhesion regulation: Na_Vβ4 appears to stabilize β-catenin, a key component of adherens junctions. Loss of Na_Vβ4 leads to increased degradation of β-catenin and reduced E-cadherin expression .

  3. Prevention of epithelial-to-mesenchymal transition (EMT): Downregulation of Na_Vβ4 induces mesenchymal markers (N-cadherin, vimentin, α-SMA) and increases proteolytic activity towards the extracellular matrix .

  Researchers can use SCN4B antibodies to:

  • Assess Na_Vβ4 expression levels in normal versus cancerous tissues

  • Perform co-immunoprecipitation studies to identify binding partners

  • Investigate the subcellular localization of Na_Vβ4 in relation to junction proteins

  • Study the expression changes during cancer progression and EMT

• How are SCN4B antibodies utilized in cancer research?

  SCN4B antibodies have become valuable tools in cancer research based on evidence that SCN4B is downregulated in several cancers including breast cancer:

  1. Expression analysis: SCN4B expression is significantly lower in all breast cancer stages compared to adjacent non-tumoral tissues, with protein expression almost 10 times lower in human mammary cancer MDA-MB-231 cells compared to non-cancer MCF10A cells .

  2. Mechanistic studies: Research has shown that Na_Vβ4 loss promotes RhoA activity and acquisition of hybrid mesenchymal-amoeboid phenotypes associated with highly invasive capacities .

  3. Potential biomarker development: The progressive downregulation of SCN4B from stage I to stage IIA breast cancer suggests it could serve as a potential early biomarker of cancer progression .

  4. Therapeutic target investigation: Understanding the role of Na_Vβ4 in maintaining epithelial phenotype may reveal new therapeutic approaches to prevent cancer progression.

  Researchers can apply SCN4B antibodies in these contexts through techniques including immunohistochemistry of tissue microarrays, Western blot analysis of cancer cell lines, and immunofluorescence studies examining subcellular localization changes during cancer progression.

Methodological Questions

• What controls should be included when using SCN4B antibodies for immunohistochemistry or immunofluorescence?

  A robust control strategy for immunohistochemistry (IHC) or immunofluorescence (IF) with SCN4B antibodies should include:

  1. Positive tissue controls:

     • Rat or mouse brain and dorsal root ganglion (DRG) tissue for Na_Vβ4 detection

     • Human tissues with known SCN4B expression (such as certain epithelial tissues)

  2. Negative controls:

     • Primary antibody omission

     • Isotype control antibody at the same concentration as the primary antibody

     • Tissues known to lack SCN4B expression

  3. Peptide competition control:

     • Pre-incubate the antibody with excess immunizing peptide

     • This should abolish specific staining as demonstrated with Anti-SCN4B (Na_Vβ4) antibodies

  4. Subcellular localization verification:

     • Na_Vβ4 is primarily detected at the cell membrane

     • In neurons, it appears in cell bodies and potentially along axons

     • In epithelial cells, it may localize to cell-cell junctions

  5. Cross-validation:

     • When possible, verify staining patterns using a different antibody targeting another epitope of SCN4B

     • Compare with mRNA expression data from the same tissues

• How can I optimize immunofluorescence protocols for detecting SCN4B in live cells?

  Live-cell SCN4B detection requires careful optimization due to the membrane localization of the protein:

  1. Antibody selection:

     • Use antibodies targeting extracellular epitopes of SCN4B, such as those recognizing the N-terminal region

     • The ASC-044 antibody targets an extracellular epitope (amino acids 85-98) and has been successfully used for live-cell staining

  2. Cell preparation:

     • Grow cells on appropriate substrates (coverslips, chamber slides)

     • For adherent cells, ensure they are well-attached but not over-confluent

     • For suspension cells, gentle centrifugation steps are needed between stainings

  3. Staining protocol:

     • Keep cells at 4°C during staining to minimize internalization

     • Use serum-free media with low BSA concentration (0.1-0.5%)

     • Dilute primary antibody appropriately (e.g., 1:50 for ASC-044)

     • Incubate 30-60 minutes at 4°C

     • Wash gently to avoid detachment

     • Use appropriate fluorophore-conjugated secondary antibody

     • Include nuclear counterstain if desired

  4. Imaging considerations:

     • Image promptly after staining

     • Maintain physiological conditions during imaging

     • Use appropriate filters to minimize phototoxicity

     • Consider Z-stack acquisition to capture the full membrane distribution

• What approaches can be used to study the interaction between SCN4B and other sodium channel subunits?

  Investigating the interactions between SCN4B and other sodium channel subunits requires specialized techniques:

  1. Co-immunoprecipitation (Co-IP):

     • Use anti-SCN4B antibodies to pull down the protein complex

     • Probe Western blots with antibodies against alpha subunits (e.g., Nav1.1, Nav1.2, Nav1.5)

     • Include appropriate controls (IgG control, lysate control)

     • Can be performed in native tissues or transfected cells

  2. Proximity Ligation Assay (PLA):

     • Requires antibodies from different species (e.g., rabbit anti-SCN4B and mouse anti-alpha subunit)

     • Provides in situ visualization of protein-protein interactions

     • Quantifiable signal indicates proximity (<40 nm)

  3. FRET/BRET analysis:

     • Requires expression of fluorescently tagged proteins

     • Measures energy transfer between closely associated proteins

     • Can provide dynamic information about interactions

  4. Cross-linking studies:

     • Chemical cross-linking followed by immunoprecipitation and mass spectrometry

     • Can identify novel interaction partners

  5. Bimolecular Fluorescence Complementation (BiFC):

     • Split fluorescent protein fragments fused to potential interacting proteins

     • Fluorescence restored upon interaction

  When using SCN4B antibodies in these approaches, it's important to verify they don't interfere with the interaction sites being studied.

• How can I quantitatively analyze SCN4B expression changes in different experimental conditions?

  Quantitative analysis of SCN4B expression requires careful experimental design and appropriate analytical methods:

  1. Western Blot Quantification:

     • Use appropriate loading controls (β-actin, GAPDH)

     • Ensure linear range of detection

     • Normalize SCN4B signal to loading control

     • Analyze using densitometry software

     • Present as fold-change relative to control condition

  2. qRT-PCR:

     • Design specific primers for SCN4B

     • Validate primer efficiency

     • Use appropriate reference genes

     • Apply ΔΔCt method for relative quantification

  3. Flow Cytometry:

     • Use extracellular-targeting SCN4B antibodies for non-permeabilized cells

     • Include isotype control and unstained control

     • Calculate median fluorescence intensity

     • Present as histograms or dot plots with statistical analysis

  4. Immunofluorescence Quantification:

     • Maintain consistent acquisition parameters

     • Analyze membrane-to-cytoplasm ratio

     • Measure co-localization with other markers

     • Use appropriate software (ImageJ, CellProfiler)

  5. Tissue Microarray Analysis:

     • Score staining intensity (0-3 scale)

     • Assess percentage of positive cells

     • Calculate H-score or other composite measures

     • Correlate with clinical parameters if applicable

  When reporting quantitative changes in SCN4B expression, include both representative images and statistical analyses of multiple independent experiments.